Alteogen Inc. disclosed an exclusive option and license agreement with Novartis Pharma AG on September 2, worth up to $3,223 million if every option is exercised and every milestone lands.
Alteogen's board approved a ₩253.2 billion plant on August 21, equal to 55.7% of 2025 equity, sixteen days after signing an ALT-B4 license worth up to $365 million.
| Symbol | Last Price |
|---|---|
| 207940Samsung Biologics Co., Ltd. | ₩1,447,000 -2.0% |
| 068270Celltrion, Inc. | ₩188,100 +0.5% |
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |